Please login to the form below

Not currently logged in
Email:
Password:

autoimmune disease

This page shows the latest autoimmune disease news and features for those working in and with pharma, biotech and healthcare.

Liver specialist Genfit files $120m IPO on Nasdaq

Liver specialist Genfit files $120m IPO on Nasdaq

Funds will go towards NASH candidate, a companion diagnostic and a liver disease drug. ... $35m has been allocated to a phase 3 trial of elafibranor in primary biliary cholangitis (PBC), a rare autoimmune disease of the liver, and $6m will go towards

Latest news

  • Horizon sunny as thyroid eye disease drug hits the mark Horizon sunny as thyroid eye disease drug hits the mark

    TED is an autoimmune disease in which the eye muscles and fatty tissue behind the eyes become inflamed, causing them to be pushed forward, and in severe cases can lead to ... At the moment proptosis is only treatable via surgery after the active disease

  • Pfizer closes on EU approval of lung cancer drug Vizimpro Pfizer closes on EU approval of lung cancer drug Vizimpro

    from Eli Lilly, as well as biosimilars of AbbVie’s blockbuster anti-TNF drug Humira (adalimumab) for inflammatory and autoimmune diseases from Fresenius Kabi  called Idacio and Kromeya. ... of moderate to severe pemphigus vulgaris (PV), an autoimmune

  • Chugai gains FDA breakthrough status for rare CNS treatment Chugai gains FDA breakthrough status for rare CNS treatment

    Satralizumab is a recycling antibody created via Chugai’s proprietary antibody engineering technologies, and works by blocking the autoimmune condition underlying NMO/NMOSD. ... NMOSD is a rare, lifelong, and debilitating autoimmune disease of the

  • Astellas, Catalyst approvals set up record year for FDA approvals Astellas, Catalyst approvals set up record year for FDA approvals

    The approvals of Astellas’ FLT3 inhibitor Xospata (gilteritinib) for acute myeloid leukaemia and Catalyst Pharmaceuticals’ Firdapse (amifampridine) for rare autoimmune disease Lambert-Eaton Myasthenic Syndrome (LEMS), already put the number for

  • Alexion targets RNAi with $637m Dicerna deal Alexion targets RNAi with $637m Dicerna deal

    The drug technology platform produces compounds that inhibit complement activation, and it can be applied across multiple therapeutic areas, including cardiovascular diseases, viral infectious disease and liver diseases. ... The new deal adds to others

More from news
Approximately 3 fully matching, plus 54 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare (part 2) 30 Women Leaders in UK Healthcare (part 2)

    ecosystem. In her 25-plus years in the sector, her investments have resulted in the launch of six drugs, spanning inflammatory and autoimmune disease and cancer.

  • Managing medication non-adherence Managing medication non-adherence

    Autoimmune conditions such as Crohn’s disease can flare up through an imbalance of things like stress, lack of sleep or overworking - not just as a direct consequence of nonadherence to

  • Reaching new heights Reaching new heights

    Transformative medicine use. The overwhelming inertia in medicine use - where 97% of medicines used have been available for more than ten years - masks the contribution from transformative disease treatments, orphan drugs ... Disease treatments in 2020

  • Pharma deals during May 2014 Pharma deals during May 2014

    Lumena develops oral products for treating liver disease and has two oral inhibitors of the apical sodium-dependent bile acid transporter (ASBT) in phase II to improve liver function. ... MGD010 a B-cell targeted monoclonal antibody for treatment of

  • The distressing impact of rare diseases The distressing impact of rare diseases

    The report found that the economic impact of a rare disease can be truly devastating. ... A UK patient with mixed connective tissue disease (an autoimmune rare disease which has the signs and symptoms of lupus, scleroderma, polymyositis, and rheumatoid

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • New hires at Nanoform, Leo Pharma and Calliditas New hires at Nanoform, Leo Pharma and Calliditas

    IgA nephropathy (IgAN) – also known as Berger’s disease. ... Currently, there are no approved treatments for IgA Nephropathy, and Nefecon has the potential to be a disease-modifying treatment for patients suffering from this chronic autoimmune disease

  • Akari Therapeutics strengthens board Akari Therapeutics strengthens board

    His expertise has seen him led transactions across a broad span of deal-types, geographies, and therapeutic disease areas and he brings experience in business and corporate development, finance, marketing and ... As Akari continues its mission to develop

  • David Horn Solomon takes the helm of Akari Therapeutics David Horn Solomon takes the helm of Akari Therapeutics

    biopharma as it focuses on the development and commercialisation of orphan autoimmune and inflammatory disease treatments.

  • Caldan Therapeutics appoints CEO Caldan Therapeutics appoints CEO

    Dr Payton joins the metabolic disease specialist - a spin-out company from the Universities of Glasgow and Southern Denmark - from MAPBiotech, where he has served as chief executive officer since 2014. ... He co-founded autoimmune disease-focused Orca

  • Santhera CEO Klaus Schollmeier joins SuppreMol Santhera CEO Klaus Schollmeier joins SuppreMol

    In his new position at autoimmune disease specialists SuppreMol, Schollmeier succeeds Professor Peter Buckell who retires. ... He said: "The company has a very promising product candidate for the treatment of autoimmune diseases in phase II clinical

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • Innovative approaches in the treatment of multiple sclerosis

    Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), leading to progressive and permanent disability. ... In RRMS symptoms are intermittent but relapses gradually become more frequent, severe and

  • The Biosimilar Challenge

    Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).

  • THE OTHER SIDE OF… CROHN’S DISEASE

    Meet Irene. Like millions of others worldwide (and an estimated 115, 000 in the UK), Irene suffers from Crohn’s disease, an autoimmune disorder that causes inflammation in the gut and ... She believes that they follow a “by-the-book” mentality, not

  • What next for the treatment of Psoriasis in Europe?

    Over the last decade, systemic biologic therapies for Psoriasis (PsO) have become widespread and the development of biological therapies has revolutionized the treatment of the disease. ... A chronic autoimmune disease, psoriasis has an estimated

  • Patient Persepective: Autoimmune Disease

    Autoimmune diseases affect 1–5% of the World’s population and have varied symptoms and causes. ... Here we explore with Lois what it is like to live with the symptoms of autoimmune disease, including Crohn’s disease, a form of inflammatory bowel

More from PMHub
Approximately 2 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics